Visa beats Q4 estimates with 13% revenue growth, but shares slip on fiscal 2027 outlook

2 min read
Visa beats Q4 estimates with 13% revenue growth, but shares slip on fiscal 2027 outlook
PrimeXBT Editorial Team
Reviewed by PrimeXBT

Topics in article

Visa beat Wall Street expectations in its fiscal fourth quarter, with net revenue up 13% to $12.1 billion. Shares still slipped in after-hours trading, suggesting investors focused more on fiscal 2027 guidance and higher renewal activity.

Visa reported net revenue of $12.1 billion, up 13% year-over-year, for its fiscal fourth quarter on October 27, 2026. Adjusted earnings per share reached $3.48, up 17%. Despite the beat, shares slipped 1.1% in after-hours trading to $397.42.

Full-year revenue hits $46 billion

Full-year net revenue reached $46 billion, up 15%, the strongest annual growth in more than 15 years excluding the post-pandemic rebound and acquisitions. Chief Executive Ryan McInerney emphasized that "2026 was a milestone year for Visa."

Business drivers were broad. Payments volume rose 9% in constant dollars, while cross-border volume excluding intra-Europe transactions grew 14%. Visa also returned $5.2 billion to shareholders in the quarter. The board raised the quarterly dividend by 16% to $0.780 per share.

Guidance points to a larger renewal cycle

For fiscal 2027, management expects net revenue growth in the low-double-digit range on a non-GAAP adjusted constant-dollar basis. Operating expense growth is also expected in the low-double-digit range.

Management noted that about 25% of payments volume is up for renewal in fiscal 2027, compared with 20% in fiscal 2026. Chief Financial Officer Chris Suh indicated these renewals are broader and include more comprehensive value-added services and commercial services. The report suggests this could mean higher incentive costs in the near term.

Client incentives already increased 21% to $5.1 billion in the quarter.

BioCatch deal awaits approval

Visa announced a definitive agreement on August 3, 2026, to acquire BioCatch, a fraud intelligence provider, for $2.4 billion in cash. The deal is subject to regulatory approvals and is expected to close by the end of fiscal second quarter 2027.

The company generated $22.1 billion in free cash flow for fiscal 2026, and its full-year share repurchases totaled $20.5 billion.

Source: Investing.com

Trading involves risk.

Most traded markets

XAU / USD
-0.05% 4,058.13
CRUDE
-0.15% 101.369
BTC / USD
+0.93% 80,831.7
EUR / USD
+0.02% 1.11280
USTEC
+0.16% 29,679.48
NFLX
-1.89% 62.45
View all markets

Author

PrimeXBT
Our Editorial Team consists of leading experts with a proven record in the fields of trading, cryptocurrencies, blockchain and finance. We thoroughly research the sources of information in order to provide readers with quality content that serves edu...
Read author’s articles
Alert Triangle Risk Disclaimer
Disclaimer: Some past publications may be outdated. We recommend following our news to stay up to date with the latest information. For any questions, feel free to contact our support team via the chat below.
The content provided here is for informational purposes only. It is not intended as personal investment advice and does not constitute a solicitation or invitation to engage in any financial transactions, investments, or related activities. Past performance is not a reliable indicator of future results.
The financial products offered by the Company are complex and come with a high risk of losing money rapidly due to leverage. These products may not be suitable for all investors. Before engaging, you should consider whether you understand how these leveraged products work and whether you can afford the high risk of losing your money.
The Company does not accept clients from the Restricted Jurisdictions as indicated in our website/ T&C. Some services or products may not be available in your jurisdiction.
The applicable legal entity and its respective products and services depend on the client’s country of residence and the entity with which the client has established a contractual relationship during registration.

Today in markets

Browse Stock News

Register Now

Trading involves risk

Get started in minutes

Our clients love how fast and simple our sign-up is. It takes just a few minutes to get started!

Get Started Get Started
Get started in minutes

Need Help?

Risk Warning:
Trading in leveraged products carries a high level of risk and may not be suitable for all investors.